LW 231
Alternative Names: LW-231Latest Information Update: 22 Oct 2024
At a glance
- Originator Longwood Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action CGAS protein modulators; Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 04 Jan 2024 LW 231 is available for licensing as of 04 Jan 2024. https://www.lwbpsh.com/en/research (Longwood Biopharma website, January 2024)
- 16 Nov 2023 Longwood Biopharma completes a phase-I trial in Hepatitis B in China (PO) (CTR20221609)
- 16 Nov 2023 Longwood Biopharma plans a phase II trial in Hepatitis B in 2024